GH Research PLC announced that the full results of its Phase 2b trial of the inhalable 5‑MeO‑DMT candidate GH001 in treatment‑resistant depression have been published in JAMA Psychiatry. The peer‑reviewed article, titled “GH001 vs Placebo in Patients with Treatment‑Resistant Depression,” presents all primary and secondary efficacy endpoints, safety data, and initial findings from the six‑month open‑label extension.
The study enrolled 300 adults with treatment‑resistant depression and reported a mean reduction in Montgomery‑Åsberg Depression Rating Scale (MADRS) scores of 15.5 points versus 4.2 points for placebo on Day 8 (P < 0.0001). Remission rates—defined as a MADRS score ≤10—were 53.9 % for GH001 and 63.6 % for placebo at Day 8, rising to 61.5 % versus 85.7 % at Month 6. A post‑hoc analysis, slated for a forthcoming issue of Psychopharmacology Bulletin, found that remission rates remained consistently high across subgroups defined by the number of prior lifetime antidepressant failures, suggesting that GH001’s benefit is independent of treatment history.
Dr. Velichka Valcheva, Chief Executive Officer, said, “Publication in JAMA Psychiatry provides independent peer‑reviewed validation of our Phase 2b findings. This supports our ongoing efforts to advance GH001 into global pivotal trials.” Michael E. Thase, MD, Professor of Psychiatry at the University of Pennsylvania, added, “One interesting, unanticipated finding from this trial is that the benefit of GH001 appeared to be independent of the number of prior lifetime antidepressant failures. Remission rates were consistently high across subgroups – in contrast to the decline seen with each successive treatment that we observed in the STAR*D trial. This suggests patients who have not responded to three or more prior courses of antidepressant therapy might benefit from this novel therapy.”
The publication marks a key milestone for GH Research, providing independent validation of clinical activity and reinforcing the company’s strategy to launch a global pivotal program in 2026. The data position GH001 ahead of competitors such as Atai Life Sciences and Compass Pathways, both of whom are developing psilocybin‑based therapies for treatment‑resistant depression. In January 2026, the FDA lifted a clinical hold on GH001, clearing the path for the planned Phase 3 initiation.
Analysts responded positively to the results, raising their outlooks on GH001’s commercial prospects. The robust, peer‑reviewed data and the finding that efficacy is maintained across patients with extensive treatment histories are viewed as a competitive advantage that could accelerate market adoption once regulatory approval is obtained.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.